<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00317486</url>
  </required_header>
  <id_info>
    <org_study_id>AC-052-405</org_study_id>
    <nct_id>NCT00317486</nct_id>
  </id_info>
  <brief_title>Effects of Tracleer (Bosentan) on Pulmonary Arterial Hypertension Related to Eisenmenger Physiology</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Tracleer (Bosentan) on Oxygen Saturation and Cardiac Hemodynamics in Patients With Pulmonary Arterial Hypertension Related to Eisenmenger Physiology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actelion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actelion</source>
  <brief_summary>
    <textblock>
      This study evaluates the effects of bosentan on oxygen saturation, hemodynamics and exercise
      capacity in patients with pulmonary arterial hypertension related to Eisenmenger physiology.
      Patients receive bosentan or placebo for 16 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">April 2005</completion_date>
  <primary_completion_date type="Actual">April 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline to Week 16 in oxygen saturation at rest with room air</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline to Week 16 in indexed pulmonary vascular resistance</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline to Week 16 in cardiac hemodynamics</measure>
  </secondary_outcome>
  <enrollment type="Actual">54</enrollment>
  <condition>Pulmonary Arterial Hypertension Related to Eisenmenger Physiology</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bosentan</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patients at least 12 years with a body weight at least 40 kg
             (inclusive) and with a functional class III (1998 WHO classification).

          2. Patients with pulmonary arterial hypertension related to Eisenmenger physiology
             echocardiographically established as atrial septal defect at least 2 cm effective
             diameter and/or ventricular septal defect at least 1 cm effective diameter; PAH
             confirmed via cardiac catheterization: mean pulmonary arterial pressure &gt;25 mm Hg,
             pulmonary capillary wedge pressure &lt;15 mm Hg and pulmonary vascular resistance &gt;3 mm
             Hg/l/min.

          3. Patients with documented oxygen saturation up to 90%, and &gt;70% (at rest, with room
             air).

          4. Patients able to perform a 6-minute walk test at least 150 m, and up to 450 m.

          5. Patients stable for at least 3 months prior to screening.

          6. Bosentan naïve patients.

          7. Female patients who are surgically sterile, postmenopausal or have documented
             infertility.

          8. Female patients of childbearing potential using one of the following methods of
             contraception: Barrier-type devices (e.g., condom, diaphragm) used ONLY in combination
             with a spermicide. A double-barrier method is recommended; intrauterine devices
             (IUDs); oral or implanted contraceptives, if used in combination with a barrier
             method.

          9. Patients providing written informed consent.

        Exclusion Criteria:

          1. Pregnant patients, nursing mothers.

          2. Patients with left ventricular dysfunction (ejection fraction &lt;40%).

          3. Patients with restrictive lung disease (TLC&lt;70% predicted); obstructive lung disease
             (FEV1&lt;70% predicted, with FEV1/FVC&lt;60%)

          4. Patients with systolic blood pressure &lt; 85 mm Hg.

          5. Patients with other conditions that may affect the ability to perform a 6-minute walk
             test.

          6. Patients unable to provide informed consent and comply with the patient protocol.

          7. Patients with known coronary arterial disease.

          8. Patients with serum creatinine &gt;125 µM/l.

          9. Patients with iron deficiency (serum ferritin &lt;10 ng/ml) unless corrected by iron
             supplement.

         10. Patients with hemoglobin or hematocrit that is more than 30% below the normal range
             (patients with secondary polycythemia are permitted).

         11. Patients with AST and/or ALT values greater than 3 times the upper limit of normal.

         12. Patients who have started or stopped treatment for PAH within one month of screening,
             excluding anticoagulation.

         13. Patients who are receiving glyburide (glibenclamide), cyclosporine A or tacrolimus at
             inclusion or are expected to receive any of these drugs during the study.

         14. Patients who are receiving vasodilators including, but not limited to epoprostenol or
             prostacyclin analogues, or are expected to receive any of these drugs during the
             study.

         15. Patients active on organ transplant lists.

         16. Patients taking phosphodiesterase inhibitors or endothelin receptor antagonists (other
             than bosentan) or any other investigational drugs/devices.

         17. Patients with planned surgical intervention during the study period.

         18. Cardiac catheterization-specific exclusion criteria:

               1. Patients who cannot safely have catheterization performed as indicated.

               2. Patients in whom shunting is not at the atrial or ventricular level.

               3. Patients with nonequal pulmonary venous desaturation that theoretically cannot be
                  corrected with administration of 100% non-rebreather-supplied oxygen.

               4. Patients with nonpulsatile pulmonary blood flow, or with multiple sources of
                  pulmonary blood flow.

               5. Patients with discontinuous pulmonary arteries, peripheral pulmonary arterial or
                  venous stenosis &gt; 25% size of native PA or creating unequal bilateral PA mean
                  pressures, PA band with gradient &gt; 20 mm Hg, tetralogy of fallot/pulmonary
                  atresia, VSD/pulmonary atresia, DORV/pulmonary atresia, truncus arteriosus,
                  scimitar syndrome.

               6. Patients where SVC sampling cannot be performed, or where SVC sampling may be
                  contaminated

               7. Patients with ductus arteriosus.

               8. Patients with mitral or pulmonary venous stenosis, intracavitary LV outflow
                  obstruction, sub, valvar or supravalvar aortic stenosis or aortic coarctation.

               9. Patients with &lt;10 indexed Wood units, greater than moderate mitral regurgitation,
                  mean pulmonary venous pressure &gt; 16 mm Hg, pulmonary venous &quot;v&quot; waves &gt; 20 mm Hg,
                  systemic ventricular end-diastolic pressure &gt; 16 mm Hg; patients with recognized
                  extracardiac systemic venous collaterals to the pulmonary venous circulation,
                  patients with recognized hepatic wedge pressure-inferior vena cava pressure
                  gradient &gt; 12 mm Hg.

              10. Patients (during catheterization) with uncorrectable hypercarbia with pCO2 &gt;55 mm
                  Hg; patients with uncorrectable acidemia with pH &lt;7.34; patients in active pain
                  or distress; unconscious or mechanically ventilated patients; patients with
                  unstable systemic or pulmonary blood flow; systemic arterial or pulmonary artery
                  pressures or hematocrit (change of &gt; 25% during catheterization); unstable
                  cardiac rhythm dissimilar to baseline cardiac rhythm during physical examination
                  assessments for the entire duration of the catheterization excepting nonsustained
                  arrhythmia; patients with documented or recognized air embolism, hemorrhage,
                  cardiac, cerebral or peripheral organ ischemia occurring during or immediately
                  preceding the catheterization.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>BACH Pulmonary Hypertension Service</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-2303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital - Central Clinical School</name>
      <address>
        <city>Camperdown</city>
        <zip>NSW 2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Melbourne Hospital</name>
      <address>
        <city>Victoria</city>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum fur Innere Medizin II</name>
      <address>
        <city>Wien</city>
        <zip>AT-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>BE-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Peter Lougheed Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T1Y 6J4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Necker-Enfants Malades</name>
      <address>
        <city>Paris</city>
        <zip>75007</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum NRW</name>
      <address>
        <city>Bad Oeynhausen</city>
        <zip>D-32545</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Munchen</name>
      <address>
        <city>Munchen</city>
        <zip>D-80636</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Bologna</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Matteo Hospital</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unidad Medico Quirurgica de Cardiologia - Edificio General</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scottish Vascular Unit - Western Infirmary</name>
      <address>
        <city>Glasgow</city>
        <zip>G11 6NT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brompton Hospital</name>
      <address>
        <city>London</city>
        <zip>SW3 6NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2006</study_first_submitted>
  <study_first_submitted_qc>April 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2006</study_first_posted>
  <disposition_first_submitted>February 11, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>February 11, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 15, 2010</disposition_first_posted>
  <last_update_submitted>February 11, 2010</last_update_submitted>
  <last_update_submitted_qc>February 11, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2010</last_update_posted>
  <keyword>pulmonary arterial hypertension</keyword>
  <keyword>Eisenmenger physiology</keyword>
  <keyword>bosentan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Eisenmenger Complex</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bosentan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

